DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.
Key Highlights from report are:
As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.
How patient subpopulations are changing the commercialization of oncology pro...IMSHealthRWES
An excerpt from the latest issue of AccessPoint, looking at how genomic profiling data is transforming our understanding of patient subpopulations - a key to targeting treatments with greater precision
This document discusses using data from the Veterans Affairs (VA) healthcare system to conduct precision oncology research. It describes extracting data from the VA Corporate Data Warehouse, including clinical records from cancer registries and records of patients who received tumor sequencing and immunotherapy. The author builds a cohort of 330 non-small cell lung cancer patients who received immunotherapy before 2018 and had their cancer verified in the registry to study outcomes like the impact of PD-L1 expression on response to treatment. Challenges include lag times in cancer registry reporting and building a large enough cohort to draw powerful conclusions from retrospective analyses.
Next generation sequencing in cancer treatment MarliaGan
Next-generation sequencing (NGS) provides several advantages over first generation sequencing methods. NGS allows large amounts of genomic information to be sequenced in parallel at a lower cost. NGS has various applications in cancer treatment including predicting cancer progression, identifying drug targets and resistance mutations, detecting minimal residual disease, and improving cancer classification. While powerful, NGS also faces limitations such as tissue heterogeneity, complexity of data analysis, and difficulties identifying driver mutations as cancers evolve with treatment.
This document discusses novel molecular therapies for hepatocellular carcinoma (HCC). It summarizes that sorafenib was the first targeted therapy shown to improve survival for advanced HCC and is now the standard of care. Several other targeted therapies are now being studied in clinical trials for HCC including anti-angiogenic agents like bevacizumab and multi-kinase inhibitors like sunitinib that target VEGF/VEGFR pathways which are important in HCC angiogenesis. Ongoing and future clinical trials of these and other targeted agents may help extend treatment options for HCC patients.
This document summarizes research on analyzing clinical and molecular cancer data to enable precision cancer medicine. It discusses analyzing tumor heterogeneity, transcriptional subtyping of colorectal cancer, identifying biomarkers of drug response, and exploring these concepts using patient-derived xenograft models. Key findings include identifying microRNAs that antagonize a poor-prognosis colorectal cancer subtype and finding kinase genes that are therapeutic targets in otherwise resistant tumor cells and xenografts.
E1512 Trial Spotlight for May 2013 ECOG-ACRIN NewsletterSara Bucknam
This trial will evaluate the efficacy and safety of erlotinib alone, cabozantinib alone, or the combination of erlotinib and cabozantinib as second- or third-line therapy for patients with EGFR wild-type non-small cell lung cancer. The trial aims to improve the modest efficacy of erlotinib by adding cabozantinib, which inhibits the MET and VEGFR pathways that are implicated in resistance to EGFR inhibitors. The primary objectives are to assess progression-free survival for the combination therapy compared to the single agents and evaluate toxicity profiles. Tissue and plasma biomarkers will also be collected to identify predictors of response.
Precision Medicine in Oncology InformaticsWarren Kibbe
This document summarizes a presentation on precision medicine in oncology from an informatics perspective. It discusses the goals of precision oncology to target cancer treatments based on a patient's individual tumor characteristics. Major initiatives are described, including the NCI-MATCH trial which assigns cancer therapies based on a tumor's molecular abnormalities. The presentation outlines efforts through the Precision Medicine Initiative to expand genomic cancer trials, understand and overcome resistance to therapies through additional tumor profiling and preclinical models, and establish an integrated national cancer database.
How patient subpopulations are changing the commercialization of oncology pro...IMSHealthRWES
An excerpt from the latest issue of AccessPoint, looking at how genomic profiling data is transforming our understanding of patient subpopulations - a key to targeting treatments with greater precision
This document discusses using data from the Veterans Affairs (VA) healthcare system to conduct precision oncology research. It describes extracting data from the VA Corporate Data Warehouse, including clinical records from cancer registries and records of patients who received tumor sequencing and immunotherapy. The author builds a cohort of 330 non-small cell lung cancer patients who received immunotherapy before 2018 and had their cancer verified in the registry to study outcomes like the impact of PD-L1 expression on response to treatment. Challenges include lag times in cancer registry reporting and building a large enough cohort to draw powerful conclusions from retrospective analyses.
Next generation sequencing in cancer treatment MarliaGan
Next-generation sequencing (NGS) provides several advantages over first generation sequencing methods. NGS allows large amounts of genomic information to be sequenced in parallel at a lower cost. NGS has various applications in cancer treatment including predicting cancer progression, identifying drug targets and resistance mutations, detecting minimal residual disease, and improving cancer classification. While powerful, NGS also faces limitations such as tissue heterogeneity, complexity of data analysis, and difficulties identifying driver mutations as cancers evolve with treatment.
This document discusses novel molecular therapies for hepatocellular carcinoma (HCC). It summarizes that sorafenib was the first targeted therapy shown to improve survival for advanced HCC and is now the standard of care. Several other targeted therapies are now being studied in clinical trials for HCC including anti-angiogenic agents like bevacizumab and multi-kinase inhibitors like sunitinib that target VEGF/VEGFR pathways which are important in HCC angiogenesis. Ongoing and future clinical trials of these and other targeted agents may help extend treatment options for HCC patients.
This document summarizes research on analyzing clinical and molecular cancer data to enable precision cancer medicine. It discusses analyzing tumor heterogeneity, transcriptional subtyping of colorectal cancer, identifying biomarkers of drug response, and exploring these concepts using patient-derived xenograft models. Key findings include identifying microRNAs that antagonize a poor-prognosis colorectal cancer subtype and finding kinase genes that are therapeutic targets in otherwise resistant tumor cells and xenografts.
E1512 Trial Spotlight for May 2013 ECOG-ACRIN NewsletterSara Bucknam
This trial will evaluate the efficacy and safety of erlotinib alone, cabozantinib alone, or the combination of erlotinib and cabozantinib as second- or third-line therapy for patients with EGFR wild-type non-small cell lung cancer. The trial aims to improve the modest efficacy of erlotinib by adding cabozantinib, which inhibits the MET and VEGFR pathways that are implicated in resistance to EGFR inhibitors. The primary objectives are to assess progression-free survival for the combination therapy compared to the single agents and evaluate toxicity profiles. Tissue and plasma biomarkers will also be collected to identify predictors of response.
Precision Medicine in Oncology InformaticsWarren Kibbe
This document summarizes a presentation on precision medicine in oncology from an informatics perspective. It discusses the goals of precision oncology to target cancer treatments based on a patient's individual tumor characteristics. Major initiatives are described, including the NCI-MATCH trial which assigns cancer therapies based on a tumor's molecular abnormalities. The presentation outlines efforts through the Precision Medicine Initiative to expand genomic cancer trials, understand and overcome resistance to therapies through additional tumor profiling and preclinical models, and establish an integrated national cancer database.
HCV research: Recent findings and future challengesMax Moldovan
The document summarizes recent findings in hepatitis C virus (HCV) research and future challenges. Three genome-wide association studies identified genetic markers associated with response to HCV treatment, including rs8099917 near the IL28B gene. While progress has been made, challenges remain in precisely determining antiviral mechanisms and accurately predicting treatment response, which requires integrating genetic, clinical, and environmental factors. Overcoming these challenges could enable personalized treatment approaches and improved drug development.
This document discusses genomic oncology and personalized medicine, using lung cancers as a model. It summarizes several key technologies that enable genomic oncology like cDNA microarrays, array CGH, and next generation sequencing. It provides examples of how these technologies have been used to classify cancers like diffuse large B-cell lymphoma and myelodysplastic syndrome, and identify genetic mutations that can guide targeted therapies for cancers like EGFR-mutated lung cancer.
This document discusses advanced non-small cell lung cancer and targeted therapies. It provides an overview of lung cancer epidemiology and risk factors like smoking. It also reviews molecular targets in NSCLC like EGFR, KRAS, and EML4-ALK and associated targeted therapies. The document outlines NSCLC diagnosis, staging, and management approaches including surgery, chemotherapy, and newer targeted therapies based on molecular profiling.
Question of Quality Conference 2016 - Jonathan B. PerlinHCA Healthcare UK
This document summarizes two case studies from HCA Healthcare that demonstrate how a large healthcare system can leverage electronic health records and data to drive quality improvement and clinical research. The first case study describes the REDUCE MRSA trial, a cluster randomized trial across 43 HCA hospitals that found universal decolonization was most effective at reducing central line-associated bloodstream infections in ICUs. The second case study found that outcomes varied for babies delivered between 37-39 weeks gestation, with 39-week babies faring best, indicating a need to carefully consider timing of elective deliveries. Both examples illustrate how HCA is able to answer important clinical questions and drive practice changes using the data and infrastructure enabled by its electronic health records
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatmentasclepiuspdfs
This document discusses strategies for overcoming resistance to EGFR tyrosine kinase inhibitors (TKIs) in the treatment of non-small cell lung cancer (NSCLC). It first provides background on EGFR and EGFR-TKIs, noting that NSCLC patients often develop resistance after about 10 months of EGFR-TKI treatment. It then summarizes the main mechanisms of resistance to EGFR-TKIs, including activation of downstream signaling pathways like RAS/RAF/MEK/ERK, activation of alternative pathways, and mutations in the EGFR kinase domain. The document focuses on targeting the RAS/RAF/MEK/ERK pathway as a strategy to overcome resistance, reviewing inhibitors in development that target
Anonymised oncology opd records research analysis report (slide share)SB BHATTACHARYYA
An analytical report of anonymised oncology OPD records with free text contents by mapping them to equivalent SNOMED CT expressions and analysing them. Text mining was also done. The purpose of the experiment conducted was to demonstrate the effectiveness of using SNOMED CT to analyse free text data. The results amply demonstrate the robustness of such an approach.
This document provides an overview of cancer of the cervix, including its epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment. It notes that cervical cancer is caused by HPV infection and discusses screening with Pap smears. Treatment options covered include surgery, radiation, chemotherapy, and management of recurrence. Prognostic factors like lymph node status and tumor size are also addressed. The goal is to educate about this largely preventable cancer.
Personalized Medicine in Diagnosis and Treatment of Cancer Maryam Rafati
The document discusses next generation sequencing (NGS) and its applications in personalized medicine for cancer diagnosis and treatment. It provides examples of several families with hereditary cancer syndromes who were analyzed using NGS to identify pathogenic variants. The results demonstrated higher response rates and prolonged progression-free and overall survival for cancer patients receiving personalized treatments based on biomarkers identified by NGS, compared to non-personalized treatments. NGS can detect somatic and germline mutations to classify cancers at a molecular level and guide precision oncology.
Clinical investigational studies for validation of a next-generation sequenci...Frank Ong, MD, CPI
Clinical investigational studies were conducted to demonstrate the accuracy and reproducibility of the Illumina MiSeqDx CF System, a next-generation sequencing (NGS) in vitro diagnostic device for cystic fibrosis testing. Two assays were evaluated in both an Accuracy Study and a Reproducibility Study, with comparison to reference methods. The studies found that both assays achieved high positive agreement, negative agreement, and overall agreement compared to reference methods. Sample pass rates were also high. This is the first systematic evaluation of a NGS platform for broad clinical use as an in vitro diagnostic for cystic fibrosis testing.
This document summarizes the results of a study on the five-year outcomes of concurrent chemoradiation therapy for locally advanced cervical cancer in Saudi women. The study found that concurrent chemoradiation resulted in 84.2% locoregional control, 78.5% distant metastasis control, and 64.5% overall survival at five years. Acute toxicity was moderate. Prognostic factors like age, comorbidities, FIGO stage, and nodal disease were also analyzed. The results were consistent with international data and support a multidisciplinary approach and use of concurrent chemoradiation as the standard of care for locally advanced cervical cancer in Saudi Arabia.
Lung cancer: a 2014 update with information about immunotherapiesZeena Nackerdien
In 2006, Dana Reeve – actress, activist, and non-smoker – died of lung cancer. In 2009, Valerie Harper – actress and “Dancing with the Stars” contestant – was diagnosed with lung cancer that has since metastasized to the brain. They are the famous faces of a disease that is the leading cause of cancer deaths. Five-year survival rates for lung cancer, the leading cause of cancer deaths, are very low. Please take a look at some of the ASCO 2014 lung cancer updates on my blog: http://norwalk.patch.com/groups/zeena-nackerdiens-blog/p/american-society-of-clinical-oncology-annual-meeting-2014-key-lung-cancer-abstracts.
Global cancer angiogenesis inhibitors market & clinical pipeline insightRajesh Sarma
“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights:
Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy
Modulators & Mechanism of Angiogenesis
Classification of Angiogenesis Inhibitors
Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy
Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs
Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs
This document provides clinical practice guidelines for the diagnosis, treatment and follow-up of metastatic non-small cell lung cancer (NSCLC) from the ESMO Guidelines Working Group. It discusses the incidence, epidemiology and risk factors for NSCLC. It recommends obtaining adequate tissue for histological diagnosis and molecular testing to guide individual treatment decisions. It also recommends testing for EGFR mutations and ALK rearrangements to identify patients eligible for targeted therapies. It provides guidance on staging workup, including imaging and laboratory tests, and staging NSCLC according to the AJCC/UICC system to determine treatment approaches.
Kurt Schalper, MD, PhD, and Edward Garon, MD, MS, prepared useful Practice Aids pertaining to immuno-oncology biomarkers for this CME/MOC activity titled "Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2DE3X9J. CME/MOC credit will be available until December 2, 2019.
Question of Quality Conference 2016 - Personalized Cancer MedicineHCA Healthcare UK
This document summarizes a presentation on personalized cancer medicine. It discusses:
1. A brief history of precision oncology, from identifying the Philadelphia chromosome in 1960 to recent advances in immunotherapy.
2. The concept of driver mutations that directly or indirectly confer growth advantages to cancer cells and have clinical implications for diagnosis, prognosis, or targeted therapies.
3. How next-generation sequencing can best identify all four classes of genomic alterations that drive tumor growth by sequencing both DNA and RNA.
4. Some case histories where genomic profiling identified targetable alterations and patients benefited from matched targeted therapies.
5. Concluding thoughts on the complexity of the cancer genome and how comprehensive genomic profiling is enabling evidence-based
This document provides an overview of non-small cell lung cancer (NSCLC). It discusses that lung cancer is the leading cause of cancer death. The majority of cases are late-stage at diagnosis and have a poor prognosis. Smoking is responsible for 90% of lung cancers. Advances in screening and targeted therapies have improved outcomes for some patients. Molecular testing is important to identify drivers and direct treatment, such as EGFR mutations that predict response to tyrosine kinase inhibitors.
The most complete map of oncogenes to date a summary of 568 oncogenes in 66 c...DoriaFang
By analyzing the genomes of 28,076 tumor samples from 66 types of cancer, 568 cancer driver genes were identified. This is the most complete map of cancer driver genes to date. The research data has been updated on the IntOGen platform.
Computational challenges in precision medicine and genomicsGary Bader
Genomics is mapping complex data about human biology and promises major medical advances. In particular, genomics is enabling precision medicine, the use of a patient's genome and physiological state to improve therapeutic efficacy and outcome. However, routine use of genomics data in medical research is in its infancy, due mainly to the challenges of working with "Big data". These data are so complex and large that typical researchers are not able to cope with them. Collectively, these data require an understanding of many aspects of experimental biology and medicine to correctly process and interpret. Data size is also an issue, as individual researchers may need to handle tens of terabytes (genomes from a few hundred patients), which is challenging to download and store on typical workstations. To effectively support precision medicine, scientists from a wide range of disciplines, including computer science, must develop algorithms to improve precision medicine (e.g. diagnostics and prognostics), genome interpretation, raw data processing and secure high performance computing.
Differences in microRNA expression during tumor development in the transition...Enrique Moreno Gonzalez
The prostate is divided into three glandular zones, the peripheral zone (PZ), the transition zone (TZ), and the central zone. Most prostate tumors arise in the peripheral zone (70-75%) and in the transition zone (20-25%) while only 10% arise in the central zone. The aim of this study was to investigate if differences in miRNA expression could be a possible explanation for the difference in propensity of tumors in the zones of the prostate.
This document provides guidelines on the diagnosis and treatment of testicular cancer and non-germ cell testicular tumours. It covers pathological classification, diagnosis, staging, treatment recommendations for stages I-III germ cell tumours including seminoma and non-seminomatous germ cell tumours, treatment of metastatic disease, follow-up care, and recommendations for testicular stromal tumours. The guidelines are based on a review of literature from 2008-2010 and are intended to help clinicians provide evidence-based care for men with testicular cancers or other testicular tumours.
Precision Medicine in Oncology InformaticsWarren Kibbe
Precision medicine in oncology aims to provide targeted cancer treatments based on a patient's individual tumor characteristics. The presentation discusses precision oncology initiatives including NCI-MATCH clinical trials which assign cancer therapies based on a tumor's molecular abnormalities rather than location. It outlines plans to expand genomically-based cancer trials, understand and overcome treatment resistance through molecular analysis, and establish a national cancer database integrating genomic and clinical data to accelerate cancer research. Cloud computing platforms are being developed to provide researchers access to large cancer genomic and clinical datasets. The goal is to advance precision cancer treatment by incorporating individual patient genetics and biomarkers into therapeutic decision making.
HCV research: Recent findings and future challengesMax Moldovan
The document summarizes recent findings in hepatitis C virus (HCV) research and future challenges. Three genome-wide association studies identified genetic markers associated with response to HCV treatment, including rs8099917 near the IL28B gene. While progress has been made, challenges remain in precisely determining antiviral mechanisms and accurately predicting treatment response, which requires integrating genetic, clinical, and environmental factors. Overcoming these challenges could enable personalized treatment approaches and improved drug development.
This document discusses genomic oncology and personalized medicine, using lung cancers as a model. It summarizes several key technologies that enable genomic oncology like cDNA microarrays, array CGH, and next generation sequencing. It provides examples of how these technologies have been used to classify cancers like diffuse large B-cell lymphoma and myelodysplastic syndrome, and identify genetic mutations that can guide targeted therapies for cancers like EGFR-mutated lung cancer.
This document discusses advanced non-small cell lung cancer and targeted therapies. It provides an overview of lung cancer epidemiology and risk factors like smoking. It also reviews molecular targets in NSCLC like EGFR, KRAS, and EML4-ALK and associated targeted therapies. The document outlines NSCLC diagnosis, staging, and management approaches including surgery, chemotherapy, and newer targeted therapies based on molecular profiling.
Question of Quality Conference 2016 - Jonathan B. PerlinHCA Healthcare UK
This document summarizes two case studies from HCA Healthcare that demonstrate how a large healthcare system can leverage electronic health records and data to drive quality improvement and clinical research. The first case study describes the REDUCE MRSA trial, a cluster randomized trial across 43 HCA hospitals that found universal decolonization was most effective at reducing central line-associated bloodstream infections in ICUs. The second case study found that outcomes varied for babies delivered between 37-39 weeks gestation, with 39-week babies faring best, indicating a need to carefully consider timing of elective deliveries. Both examples illustrate how HCA is able to answer important clinical questions and drive practice changes using the data and infrastructure enabled by its electronic health records
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatmentasclepiuspdfs
This document discusses strategies for overcoming resistance to EGFR tyrosine kinase inhibitors (TKIs) in the treatment of non-small cell lung cancer (NSCLC). It first provides background on EGFR and EGFR-TKIs, noting that NSCLC patients often develop resistance after about 10 months of EGFR-TKI treatment. It then summarizes the main mechanisms of resistance to EGFR-TKIs, including activation of downstream signaling pathways like RAS/RAF/MEK/ERK, activation of alternative pathways, and mutations in the EGFR kinase domain. The document focuses on targeting the RAS/RAF/MEK/ERK pathway as a strategy to overcome resistance, reviewing inhibitors in development that target
Anonymised oncology opd records research analysis report (slide share)SB BHATTACHARYYA
An analytical report of anonymised oncology OPD records with free text contents by mapping them to equivalent SNOMED CT expressions and analysing them. Text mining was also done. The purpose of the experiment conducted was to demonstrate the effectiveness of using SNOMED CT to analyse free text data. The results amply demonstrate the robustness of such an approach.
This document provides an overview of cancer of the cervix, including its epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment. It notes that cervical cancer is caused by HPV infection and discusses screening with Pap smears. Treatment options covered include surgery, radiation, chemotherapy, and management of recurrence. Prognostic factors like lymph node status and tumor size are also addressed. The goal is to educate about this largely preventable cancer.
Personalized Medicine in Diagnosis and Treatment of Cancer Maryam Rafati
The document discusses next generation sequencing (NGS) and its applications in personalized medicine for cancer diagnosis and treatment. It provides examples of several families with hereditary cancer syndromes who were analyzed using NGS to identify pathogenic variants. The results demonstrated higher response rates and prolonged progression-free and overall survival for cancer patients receiving personalized treatments based on biomarkers identified by NGS, compared to non-personalized treatments. NGS can detect somatic and germline mutations to classify cancers at a molecular level and guide precision oncology.
Clinical investigational studies for validation of a next-generation sequenci...Frank Ong, MD, CPI
Clinical investigational studies were conducted to demonstrate the accuracy and reproducibility of the Illumina MiSeqDx CF System, a next-generation sequencing (NGS) in vitro diagnostic device for cystic fibrosis testing. Two assays were evaluated in both an Accuracy Study and a Reproducibility Study, with comparison to reference methods. The studies found that both assays achieved high positive agreement, negative agreement, and overall agreement compared to reference methods. Sample pass rates were also high. This is the first systematic evaluation of a NGS platform for broad clinical use as an in vitro diagnostic for cystic fibrosis testing.
This document summarizes the results of a study on the five-year outcomes of concurrent chemoradiation therapy for locally advanced cervical cancer in Saudi women. The study found that concurrent chemoradiation resulted in 84.2% locoregional control, 78.5% distant metastasis control, and 64.5% overall survival at five years. Acute toxicity was moderate. Prognostic factors like age, comorbidities, FIGO stage, and nodal disease were also analyzed. The results were consistent with international data and support a multidisciplinary approach and use of concurrent chemoradiation as the standard of care for locally advanced cervical cancer in Saudi Arabia.
Lung cancer: a 2014 update with information about immunotherapiesZeena Nackerdien
In 2006, Dana Reeve – actress, activist, and non-smoker – died of lung cancer. In 2009, Valerie Harper – actress and “Dancing with the Stars” contestant – was diagnosed with lung cancer that has since metastasized to the brain. They are the famous faces of a disease that is the leading cause of cancer deaths. Five-year survival rates for lung cancer, the leading cause of cancer deaths, are very low. Please take a look at some of the ASCO 2014 lung cancer updates on my blog: http://norwalk.patch.com/groups/zeena-nackerdiens-blog/p/american-society-of-clinical-oncology-annual-meeting-2014-key-lung-cancer-abstracts.
Global cancer angiogenesis inhibitors market & clinical pipeline insightRajesh Sarma
“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights:
Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy
Modulators & Mechanism of Angiogenesis
Classification of Angiogenesis Inhibitors
Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy
Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs
Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs
This document provides clinical practice guidelines for the diagnosis, treatment and follow-up of metastatic non-small cell lung cancer (NSCLC) from the ESMO Guidelines Working Group. It discusses the incidence, epidemiology and risk factors for NSCLC. It recommends obtaining adequate tissue for histological diagnosis and molecular testing to guide individual treatment decisions. It also recommends testing for EGFR mutations and ALK rearrangements to identify patients eligible for targeted therapies. It provides guidance on staging workup, including imaging and laboratory tests, and staging NSCLC according to the AJCC/UICC system to determine treatment approaches.
Kurt Schalper, MD, PhD, and Edward Garon, MD, MS, prepared useful Practice Aids pertaining to immuno-oncology biomarkers for this CME/MOC activity titled "Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2DE3X9J. CME/MOC credit will be available until December 2, 2019.
Question of Quality Conference 2016 - Personalized Cancer MedicineHCA Healthcare UK
This document summarizes a presentation on personalized cancer medicine. It discusses:
1. A brief history of precision oncology, from identifying the Philadelphia chromosome in 1960 to recent advances in immunotherapy.
2. The concept of driver mutations that directly or indirectly confer growth advantages to cancer cells and have clinical implications for diagnosis, prognosis, or targeted therapies.
3. How next-generation sequencing can best identify all four classes of genomic alterations that drive tumor growth by sequencing both DNA and RNA.
4. Some case histories where genomic profiling identified targetable alterations and patients benefited from matched targeted therapies.
5. Concluding thoughts on the complexity of the cancer genome and how comprehensive genomic profiling is enabling evidence-based
This document provides an overview of non-small cell lung cancer (NSCLC). It discusses that lung cancer is the leading cause of cancer death. The majority of cases are late-stage at diagnosis and have a poor prognosis. Smoking is responsible for 90% of lung cancers. Advances in screening and targeted therapies have improved outcomes for some patients. Molecular testing is important to identify drivers and direct treatment, such as EGFR mutations that predict response to tyrosine kinase inhibitors.
The most complete map of oncogenes to date a summary of 568 oncogenes in 66 c...DoriaFang
By analyzing the genomes of 28,076 tumor samples from 66 types of cancer, 568 cancer driver genes were identified. This is the most complete map of cancer driver genes to date. The research data has been updated on the IntOGen platform.
Computational challenges in precision medicine and genomicsGary Bader
Genomics is mapping complex data about human biology and promises major medical advances. In particular, genomics is enabling precision medicine, the use of a patient's genome and physiological state to improve therapeutic efficacy and outcome. However, routine use of genomics data in medical research is in its infancy, due mainly to the challenges of working with "Big data". These data are so complex and large that typical researchers are not able to cope with them. Collectively, these data require an understanding of many aspects of experimental biology and medicine to correctly process and interpret. Data size is also an issue, as individual researchers may need to handle tens of terabytes (genomes from a few hundred patients), which is challenging to download and store on typical workstations. To effectively support precision medicine, scientists from a wide range of disciplines, including computer science, must develop algorithms to improve precision medicine (e.g. diagnostics and prognostics), genome interpretation, raw data processing and secure high performance computing.
Differences in microRNA expression during tumor development in the transition...Enrique Moreno Gonzalez
The prostate is divided into three glandular zones, the peripheral zone (PZ), the transition zone (TZ), and the central zone. Most prostate tumors arise in the peripheral zone (70-75%) and in the transition zone (20-25%) while only 10% arise in the central zone. The aim of this study was to investigate if differences in miRNA expression could be a possible explanation for the difference in propensity of tumors in the zones of the prostate.
This document provides guidelines on the diagnosis and treatment of testicular cancer and non-germ cell testicular tumours. It covers pathological classification, diagnosis, staging, treatment recommendations for stages I-III germ cell tumours including seminoma and non-seminomatous germ cell tumours, treatment of metastatic disease, follow-up care, and recommendations for testicular stromal tumours. The guidelines are based on a review of literature from 2008-2010 and are intended to help clinicians provide evidence-based care for men with testicular cancers or other testicular tumours.
Precision Medicine in Oncology InformaticsWarren Kibbe
Precision medicine in oncology aims to provide targeted cancer treatments based on a patient's individual tumor characteristics. The presentation discusses precision oncology initiatives including NCI-MATCH clinical trials which assign cancer therapies based on a tumor's molecular abnormalities rather than location. It outlines plans to expand genomically-based cancer trials, understand and overcome treatment resistance through molecular analysis, and establish a national cancer database integrating genomic and clinical data to accelerate cancer research. Cloud computing platforms are being developed to provide researchers access to large cancer genomic and clinical datasets. The goal is to advance precision cancer treatment by incorporating individual patient genetics and biomarkers into therapeutic decision making.
This presentation gives an overview on available and future therapies for Small Cell Lung Cancer (SCLC). It covers topics on potential therapeutic targets, genomics, translational medicine, clinical research and market analysis.
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...JohnJulie1
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...AnonIshanvi
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...daranisaha
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...EditorSara
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability..
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...semualkaira
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability..
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...semualkaira
Lung cancer is the second common malignancy and the most aggressive cancer worldwide with late diagnosis and poor prognosis. The search for biomarkers that promote early diagnosis and improve therapeutic strategies focuses to the understanding of the mechanisms underlying cancer development and progression. The deregulation of gene expression is one of the cancer hallmarks reflected to the stability...
Deadenylase Expression in Small Cell Lung Cancer Related To Clinical Characte...NainaAnon
This study examined the expression levels of deadenylases in small cell lung cancer (SCLC) clinical samples and their correlation to patient clinical characteristics and survival. Real-time PCR analysis found that the deadenylases PARN, CNOT6, CNOT7, and NOC were differentially expressed between malignant and normal lung tissue samples. Higher expression levels of PARN, CNOT6, and CNOT7 correlated with older patient age and decreased overall survival of 180 days or less. The results suggest these deadenylases may serve as prognostic biomarkers for SCLC patient outcomes.
This document summarizes Targovax's approach to activating the immune system to fight cancer. It discusses moving from sequential treatment strategies like surgery, radiation, and chemotherapy to a combination approach harnessing the immune system. Targovax's focus is on immune activators like oncolytic viruses and vaccines to make cancer visible to the immune system. The document outlines Targovax's clinical programs using oncolytic viruses ONCOS and therapeutic cancer vaccine TG, including current and planned trials in cancers like mesothelioma, melanoma, and colorectal cancer. Early data from a phase I/II trial of ONCOS-102 in mesothelioma shows safety and signs of efficacy.
Global & usa cancer immunotherapy market analysis to 2020Research Hub
This document provides an overview and analysis of the global cancer immunotherapy market from 2014 to 2020. It discusses the types of immunotherapies available including monoclonal antibodies, cancer vaccines, and non-specific therapies. It analyzes current trends in immunotherapies such as anti-PD-1 drugs, dendritic cell vaccines, T-cell therapies, and cancer vaccines. It also provides market size data for cancer immunotherapies by geography, indication, company, and individual drugs.
Efficacy of Apatinib+Radiotherapy Vs. Radiotherapy Alone in Patients with Adv...semualkaira
The median intracranial PFS for the RT group and
Apatinib+RT group was 5.83 months and 11.81 months (p=0.034).
The median OS for the RT group and Apatinib+RT group was 9.02
months and 13.62 months (p=0.311). The Apatinib+RT group had
a better intracranial PFS, but there were no significant differences
between the two arms in OS. The Apatinib+RT group had significantly reduced symptoms caused by BM, mainly headache and
vomiting. Most patients tolerated the side effects well
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
This document discusses Targovax's focus on immune activators to treat cancer. It summarizes:
1) Targovax's approach of using oncolytic viruses and vaccines to activate T-cells to target tumors, rather than directly targeting cancer through surgery, radiation, or chemotherapy.
2) Targovax's two programs - ONCOS, an oncolytic virus, and TG, a therapeutic cancer vaccine - and their clinical development strategies.
3) Early positive results from a Phase I/II trial of ONCOS-102 for malignant pleural mesothelioma, with the drug showing safety, innate and adaptive immune activation, and early signs of clinical activity.
16 cco korean perspectives of nasopharynx cancer managementYong Chan Ahn
This document discusses nasopharynx cancer (NPC) in Korea. It begins by providing background on NPC epidemiology and the association between NPC subtypes and Epstein-Barr virus prevalence. It then discusses the establishment of a Korean NPC database and findings from analyses of the database. Key findings include improvements in survival over time associated with advances in imaging, radiation technique, and use of concurrent chemotherapy. Studies from the database found concurrent chemoradiation is optimal for stage II NPC and that neoadjuvant or adjuvant chemotherapy did not provide additional benefits when added to concurrent chemoradiation for advanced stages.
This document outlines the rationale, objectives, hypotheses, study design, and planned analyses for investigating the potential association between calcium channel blocker (CCB) use and cancer risk. The study will be conducted using multiple epidemiological databases from the UK, Denmark, Netherlands, Spain, and Germany. The specific objectives are to conduct descriptive studies, a population-based cohort study, and nested case-control analyses to compare cancer outcomes between CCB users and non-users. The primary outcome of interest is risk of all cancers combined, and secondary outcomes include breast, prostate, and colon cancers analyzed separately.
Sk microfluidics and lab on-a-chip-ch6stanislas547
This document discusses cancer diagnostics and monitoring using microfluidic lab-on-a-chip technologies. It describes how integrating DNA/protein separation, detection, and analysis into microfluidic chips could allow for frequent, non-invasive testing of cancer biomarkers in blood or other bodily fluids. This would enable more precise monitoring of cancer treatment effectiveness and earlier detection of recurrence compared to standard techniques. The document outlines approaches involving microfluidic separation channels coupled to molecular detection and proposes a credit card-sized disposable chip sensor integrated with a small control unit for point-of-care cancer screening and monitoring.
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline.
Similar to Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030 (20)
The most thrilling international pharma events, from conferences to meetings & workshops, this is the list not to be missed for pharma professionals.
Check out our list of Top 10 Pharmaceutical conferences:
1. International Conference on Cell and Gene Therapy
2. BIO-Europe Spring 2021
3. DUPHAT- 2021 : https://duphat.ae/
4. CPHI India 2021
5. DIA Europe 2021
6. BIO Asia International Conference 2021
7. BIO International Convention
8. CAR TCR EUROPE 2021
9. Pharma Forum 2021
10. 4th Annual Bioprocessing Summit Europe
DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market
The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.
This document provides a list of the top 10 international cell therapy conferences in 2020. The conferences cover topics related to cell and gene therapy research and applications, including CAR-T cell therapies, regenerative medicine, tissue engineering, bioprocessing, manufacturing, and clinical trials. The conferences will take place in various locations around the world, including Europe, Asia, and North America, between February and October 2020.
Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules to the ampulla of Vater, and at the peribiliary glands.
Charcot Marie tooth disease is one of the hereditary motor and sensory neuropathies, a group of varied inherited disorders of the peripheral nervous system characterized by progressive loss of muscle tissue and touch sensation across various parts of the body.
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening severe orphan disease in which the air sacs present in alveoli are filled with fluid and lower the amount of oxygen in the blood. Thus, enough oxygen is not supplied to the body. Inflammation may occur throughout the lungs.
Acute Bacterial Skin and Skin-Structure Infection-ABSSSIDr. B.K. Agrawal
DelveInsight’s ABSSSI market report gives a thorough understanding of Acute Bacterial Skin and Skin-Structure Infection. It provides ABSSSI treatment algorithms and ABSSSI treatment guidelines in the US, Europe, and Japan. The ABSSSI market outlook of the report helps to build the detailed comprehension of the historical, current and forecasted trend of the ABSSSI market by analysing the impact of current therapies on the market, unmet needs, ABSSSI market drivers and ABSSSI market barriers and demand of better technology.
For more information on ABSSSI market, click here: <a href="https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast">ABSSSI Market</a>
This document provides an overview and market insights into house dust mite allergy (HDMA). It discusses that HDMA is an allergic reaction to dust mites commonly found in house dust. The two main species that cause allergy reactions are Dermatophagoides pteronyssinus and Dermatophagoides farinae. Signs of dust mite allergy include sneezing, runny nose and other hay fever-like symptoms. Dust mites thrive in warm, humid environments. The document reviews prevalence, diagnosed cases, treatment guidelines, marketed products and upcoming therapies. It provides market size data by region and forecasts growth during 2018-2027 due to new product launches. Major players in the HDMA
Allergic rhinitis, also known as hay fever, is a type
of inflammation in the nose which occurs when
the immune system overreacts to allergens in the
air. Signs and symptoms include a runny or stuffy
nose, sneezing, red, itchy, and watery eyes, and
swelling around the eyes.
Solution manual for managerial accounting 18th edition by ray garrison eric n...rightmanforbloodline
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Health Tech Market Intelligence Prelim Questions -Gokul Rangarajan
The Ultimate Guide to Setting up Market Research in Health Tech part -1
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
This lays foundation of scoping research project what are the
Before embarking on a research project, especially one aimed at scoping and defining parameters like the one described for health tech IT, several crucial considerations should be addressed. Here’s a comprehensive guide covering key aspects to ensure a well-structured and successful research initiative:
1. Define Research Objectives and Scope
Clear Objectives: Define specific goals such as understanding market needs, identifying new opportunities, assessing risks, or refining pricing strategies.
Scope Definition: Clearly outline the boundaries of the research in terms of geographical focus, target demographics (e.g., age, socio-economic status), and industry sectors (e.g., healthcare IT).
3. Review Existing Literature and Resources
Literature Review: Conduct a thorough review of existing research, market reports, and relevant literature to build foundational knowledge.
Gap Analysis: Identify gaps in existing knowledge or areas where further exploration is needed.
4. Select Research Methodology and Tools
Methodological Approach: Choose appropriate research methods such as surveys, interviews, focus groups, or data analytics.
Tools and Resources: Select tools like Google Forms for surveys, analytics platforms (e.g., SimilarWeb, Statista), and expert consultations.
5. Ethical Considerations and Compliance
Ethical Approval: Ensure compliance with ethical guidelines for research involving human subjects.
Data Privacy: Implement measures to protect participant confidentiality and adhere to data protection regulations (e.g., GDPR, HIPAA).
6. Budget and Resource Allocation
Resource Planning: Allocate resources including time, budget, and personnel required for each phase of the research.
Contingency Planning: Anticipate and plan for unforeseen challenges or adjustments to the research plan.
7. Develop Research Instruments
Survey Design: Create well-structured surveys using tools like Google Forms to gather quantitative data.
Interview and Focus Group Guides: Prepare detailed scripts and discussion points for qualitative data collection.
8. Sampling Strategy
Sampling Design: Define the sampling frame, size, and method (e.g., random sampling, stratified sampling) to ensure representation of target demographics.
Participant Recruitment: Plan recruitment strategies to reach and engage the intended participant groups effectively.
9. Data Collection and Analysis Plan
Data Collection: Implement methods for data gathering, ensuring consistency and validity.
Analysis Techniques: Decide on analytical approaches (e.g., statistical
Emotional and Behavioural Problems in Children - Counselling and Family Thera...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdfSachin Sharma
Here are some key objectives of communication with children:
Build Trust and Security:
Establish a safe and supportive environment where children feel comfortable expressing themselves.
Encourage Expression:
Enable children to articulate their thoughts, feelings, and experiences.
Promote Emotional Understanding:
Help children identify and understand their own emotions and the emotions of others.
Enhance Listening Skills:
Develop children’s ability to listen attentively and respond appropriately.
Foster Positive Relationships:
Strengthen the bond between children and caregivers, peers, and other adults.
Support Learning and Development:
Aid cognitive and language development through engaging and meaningful conversations.
Teach Social Skills:
Encourage polite, respectful, and empathetic interactions with others.
Resolve Conflicts:
Provide tools and guidance for children to handle disagreements constructively.
Encourage Independence:
Support children in making decisions and solving problems on their own.
Provide Reassurance and Comfort:
Offer comfort and understanding during times of distress or uncertainty.
Reinforce Positive Behavior:
Acknowledge and encourage positive actions and behaviors.
Guide and Educate:
Offer clear instructions and explanations to help children understand expectations and learn new concepts.
By focusing on these objectives, communication with children can be both effective and nurturing, supporting their overall growth and well-being.
nursing management of patient with Empyema pptblessyjannu21
prepared by Prof. BLESSY THOMAS, SPN
Empyema is a disease of respiratory system It is defines as the accumulation of thick, purulent fluid within the pleural space, often with fibrin development.
Empyema is also called pyothorax or purulent pleuritis.
It’s a condition in which pus gathers in the area between the lungs and the inner surface of the chest wall. This area is known as the pleural space.
Pus is a fluid that’s filled with immune cells, dead cells, and bacteria.
Pus in the pleural space can’t be coughed out. Instead, it needs to be drained by a needle or surgery.
Empyema usually develops after pneumonia, which is an infection of the lung tissue. it is mainly caused due in infectious micro-organisms. It can be treated with medications and other measures.
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...The Lifesciences Magazine
The cyclothymia test is a pivotal tool in the diagnostic process. It helps clinicians assess the presence and severity of symptoms associated with cyclothymia.
At Malayali Kerala Spa Ajman we providing the top quality massage services for our customers.
Our massage center prioritizes efficiency to ensure a quality massage experience for our clients at Malayali Kerala Spa Ajman. We offer a convenient appointment system and precise massage services.
Reach us at Villa No 7, Near Ammar Bin Yasir Street Al Rashidiya 2 - Ajman - United Arab Emirates.
Phone : +971 529818279
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPTblessyjannu21
Prepared by Prof. BLESSY THOMAS, VICE PRINCIPAL, FNCON, SPN.
Emphysema is a disease condition of respiratory system.
Emphysema is an abnormal permanent enlargement of the air spaces distal to terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis.
Emphysema of lung is defined as hyper inflation of the lung ais spaces due to obstruction of non respiratory bronchioles as due to loss of elasticity of alveoli.
It is a type of chronic obstructive
pulmonary disease.
It is a progressive disease of lungs.
Fit to Fly PCR Covid Testing at our Clinic Near YouNX Healthcare
A Fit-to-Fly PCR Test is a crucial service for travelers needing to meet the entry requirements of various countries or airlines. This test involves a polymerase chain reaction (PCR) test for COVID-19, which is considered the gold standard for detecting active infections. At our travel clinic in Leeds, we offer fast and reliable Fit to Fly PCR testing, providing you with an official certificate verifying your negative COVID-19 status. Our process is designed for convenience and accuracy, with quick turnaround times to ensure you receive your results and certificate in time for your departure. Trust our professional and experienced medical team to help you travel safely and compliantly, giving you peace of mind for your journey.www.nxhealthcare.co.uk
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...Media Logic
When it comes to creating marketing strategies that target older adults, it is crucial to have insight into their media habits and preferences. Understanding how older adults consume and use media is key to creating acquisition and retention strategies. We recently conducted our seventh annual survey to gain insight into the media preferences of older adults in 2024. Here are the survey responses and marketing implications that stood out to us.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
English Drug and Alcohol Commissioners June 2024.pptxMatSouthwell1
Presentation made by Mat Southwell to the Harm Reduction Working Group of the English Drug and Alcohol Commissioners. Discuss stimulants, OAMT, NSP coverage and community-led approach to DCRs. Focussing on active drug user perspectives and interests
Hyderabad Call Girls 7023059433 High Profile Escorts Service Hyderabad
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030
1. Non-Small Cell Lung Cancer Market
Analysis, Market Share, Market Research
Report, Leading Companies
LAS VEGAS, April 28, 2020 -- The growth of NSCLC Market is expected to
increase due to increasing incident cases of NSCLC, continuous uptake of
approved therapies mainly immune checkpoint inhibitors, increasing use of
biomarker testing, probable entry of potential premium price emerging
therapies and increasing awareness of mutations, among others.
DelveInsight has introduced a new Market Insights, Epidemiology, and Market
Forecast Report on "Non-Small Cell Lung Cancer Market Insights,
Epidemiology, and Market Forecast-2030" to its portfolio.
Key Highlights from report are:
As per the DelveInsight analysis, the total incident cases of NSCLC in the
7MM were observed to be 484,726 cases in the year 2017. These cases
are expected to grow with a significant CAGR in the study period 2017–
2030.
There are different types of treatment available for NSCLC; however,
mainly 10 types of standard treatment are used, which include Surgery,
Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy,
Laser therapy, Photodynamic therapy (PDT), Cryosurgery,
Electrocautery, and Watchful waiting.
The market size of NSCLC in the 7MM is expected to increase during
study period. According to the estimates, the highest contribution in the
market size of NSCLC is from the United States followed
by Japan, Germany, and the UK.
2. One of the most exciting developments in lung cancer medicine is the
introduction of targeted treatments.
Request for free sample pages to know more on Non-Small Cell Lung Cancer
Market Forecast
NSCLC is the most common type of lung cancer accounted for approximately
85% of all lung cancers. The disease epidemiology included in the report
provides historical as well as forecasted Non-Small Cell Lung Cancer
epidemiology, which is segmented as Total Incident cases of NSCLC patients,
Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of
NSCLC patients by Stages, Total NSCLC cases of patients by Genetic
mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of
Therapies scenario of NSCLC in the 7MM.
The total NSCLC incident cases in the 7MM were observed to be 484,726 cases
in 2017.
3. Click here to know more on Non-Small Cell Lung Cancer pipeline
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer
marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek
(Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq
(Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in
combination with Mekinist (Trametinib), Tagrisso (osimertinib),
Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib),
Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along
with many more.
Drugs covered in the report are:-
There are several key players robustly involved in developing potential
products such as
Nazartinib (EGF816)
Capmatinib (INC280)
Tepmetko (tepotinib)
Merestinib
JNJ-61186372 (JNJ-6372)
Vemurafenib Plus Cobimetinib
X-396 (Ensartinib)
Tedopi (OSE2101)
Selpercatinib (LY3527723/ LOXO-292)
SAR408701
Braftovi (encorafinib) + Mektovi (binimetinib)
PADCEV (enfortumab vedotin/ASG-22ME)
Pralsetinib (BLU-667)
TAK-788: Canakinumab (ACZ885)
Avelumab (Bavencio)
Veliparib (ABT-888): Sitravatinib (MGCD516)
Tesevatinib
Romiplostim: Cabozantinib
Sym015
AMG 510
INCMGA00012 (MGA012)
4. Libtayo (Cemiplimab)
Bavituximab
M7824 (Bintrafusp alfa)
And many others
Key Players covered in the report are:-
Novartis Pharmaceuticals
Merck KGaA
Eli Lilly and Company
Janssen Research & Development
Hoffmann-La Roche
Xcovery
BeyondSpring Pharmaceuticals
OSE Immunotherapeutics
Sanofi
Pfizer
Astellas Pharma
Seattle Genetics
Blueprint Medicines Corporation
Takeda
AbbVie
Kadmon Corporation
Amgen
Symphogen
Regeneron Pharmaceuticals
Peregrine Pharmaceuticals
Avid Bioservices
GlaxoSmithKline
And many others
The report includes provides in depth analysis historical and forecasted Market
Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by
Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of
BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total
Market Size of ALK as well.
Market Driver
5. Market Barrier
The reasons for buying this report:
The report proffers an overview of pathophysiology, various diagnostic
approaches and NSCLC treatment algorithm, including detailed chapters
for marketed products and emerging therapies.
Historical and forecasted Non-Small Cell Lung Cancer epidemiology in
7MM covering the United States, EU5 (Germany, France, Italy, Spain,
and the United Kingdom), and Japan from 2017-2030.
Detailed historical and forecasted NSCLC market covering the United
States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and
Phase II), different emerging trends and comparative analysis of pipeline
products with comprehensive clinical profiles, key cross-competition,
launch date along with product development activities.
Detailed Non-Small Cell Lung Cancer market size by therapies,
covering the United States, EU5 and Japan from 2017-2030.
6. Reimbursement scenario and Key Opinion Leader Views
Table of Contents
1. Key Insights
2. Executive Summary of NSCLC
3. SWOT Analysis of NSCLC
4. NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country
4.3. Total Market Share (%) Distribution of NSCLC in 2017: By Mutations/
biomarkers
4.4. Total Market Share (%) Distribution of NSCLC in 2030: By Mutations/
biomarkers
4.5. NSCLC Revenue Summary by Mutations/ biomarkers
5. Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC
6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
7. 6.2. Stages of NSCLC
6.3. Staging System
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the
United States
8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in
Germany
8.2. France
8. 8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United
Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United
Kingdom
8.5.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the
United Kingdom
9. Japan Epidemiology
9.1. Japan
9. 9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan
10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC
11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines:
2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice
Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines:
2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018
12. Unmet Needs of NSCLC
13. Key Endpoints in NSCLC Clinical Trials
14. Marketed Therapies
14.1. Key Cross
13. 14.13. Vitrakvi (Larotrectinib): Bayer Healthcare
14.13.1. Product Description
14.13.2. Regulatory Milestones
14.13.3. Other Developmental Activities
14.13.4. Pivotal Clinical Trials
14.13.5. Safety and Efficacy
14.14. Portrazza (Necitumumab): Eli Lilly
14.14.1. Product Description
14.14.2. Regulatory Milestones
14.14.3. Other Developmental Activities
14.14.4. Pivotal Clinical Trials
14.14.5. Ongoing Current Pipeline Activity
15. Emerging Therapies
15.1. Nazartinib (EGF816): Novartis Pharmaceuticals
15.1.1. Product Description
15.1.2. Clinical Development
15.1.3. Safety and Efficacy
15.2. Capmatinib (INC280): Novartis Pharmaceuticals
15.2.1. Product Description
15.2.2. Other Development Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
14. 15.3. Tepmetko (tepotinib): Merck KGaA
15.3.1. Product Description
15.3.2. Other Development Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. Merestinib: Eli Lilly and Company
15.4.1. Product Description
15.4.2. Clinical Development
15.4.3. Telisotuzumab Vedotin: AbbVie
15.4.4. Product Description
15.4.5. Clinical Development
15.4.6. Safety and Efficacy
15.5. JNJ-61186372 (JNJ-6372): Janssen Research & Development
15.5.1. Product Description
15.5.2. Other Development Activity
15.5.3. Clinical Development
15.5.4. Safety and Efficacy
15.6. Lazertinib: Yuhan Corporation/ Janssen Research & Development
15.6.1. Product Description
15.6.2. Clinical Development
15.6.3. Safety and Efficacy
15.7. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche
15. 15.7.1. Product Description
15.7.2. Clinical Development
15.7.3. Safety and Efficacy
15.8. X-396 (Ensartinib): Xcovery
15.8.1. Product Description
15.8.2. Clinical Development
15.8.3. Safety and Efficacy
15.9. Plinabulin: BeyondSpring Pharmaceuticals
15.9.1. Product Description
15.9.2. Clinical Development
15.9.3. Safety and Efficacy
15.10. Tedopi (OSE2101): OSE Immunotherapeutics
15.10.1. Product Description
15.10.2. Clinical Development
15.10.3. Safety and Efficacy
15.11. Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company
15.11.1. Product Description
15.11.2. Clinical Development
15.11.3. Safety and Efficacy
15.12. SAR408701: Sanofi
15.12.1. Product Description
15.12.2. Clinical Development
16. 15.13. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer
15.13.1. Product Description
15.13.2. Clinical Development
15.14. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle
Genetics
15.14.1. Product Description
15.14.2. Clinical Development
15.15. Pralsetinib (BLU-667): Blueprint Medicines Corporation
15.15.1. Product Description
15.15.2. Clinical Development
15.15.3. Safety and Efficacy
15.16. TAK-788: Takeda
15.16.1. Product Description
15.16.2. Clinical Development
15.16.3. Safety and Efficacy
15.17. Canakinumab (ACZ885): Novartis Pharmaceuticals
15.17.1. Product Description
15.17.2. Clinical Development
15.18. Avelumab (Bavencio): Merck KGaA and Pfizer
15.18.1. Product Description
15.18.2. Clinical Development
15.18.3. Safety and Efficacy
15.19. Veliparib (ABT-888): AbbVie
17. 15.19.1. Product Description
15.19.2. Clinical Development
15.19.3. Safety and Efficacy
15.20. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers
Squibb/Beigene
15.20.1. Product Description
15.20.2. Other Developmental Activities
15.20.3. Clinical Development
15.20.4. Safety and Efficacy
15.21. Tesevatinib: Kadmon Corporation
15.21.1. Product Description
15.21.2. Clinical Development
15.21.3. Safety and Efficacy
15.22. Romiplostim: Amgen
15.22.1. Product Description
15.22.2. Clinical Development
15.23. Cabozantinib: Exelixis/Ipsen/Takeda
15.23.1. Product Description
15.23.2. Other Development Activities
15.23.3. Clinical Development
15.23.4. Safety and Efficacy
15.24. Sym015: Symphogen
15.24.1. Product Description
18. 15.24.2. Clinical Development
15.24.3. Safety and Efficacy
15.25. AMG 510: Amgen
15.25.1. Product Description
15.25.2. Clinical Development
15.25.3. Safety and Efficacy
15.26. INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited
15.26.1. Product Description
15.26.2. Clinical Development
15.27. Libtayo (Cemiplimab): Regeneron Pharmaceuticals
15.27.1. Product Description
15.27.2. Clinical Development
15.27.3. Safety and Efficacy
15.28. Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc
15.28.1. Product Description
15.28.2. Clinical Development
15.28.3. Safety and Efficacy
15.29. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA
15.29.1. Product Description
15.29.2. Clinical Development
15.29.3. Safety and Efficacy
16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
19. 16.1. Key Findings
16.2. Market Outlook: 7MM
17. PD-L1—Market Size
17.1. Total Market Size of PD-L1 NSCLC in the 7MM
17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.3.1. Total Market size of PD-L1 NSCLC in the United States
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
17.5.1. Total Market size of PD-L1 NSCLC in Japan
18. BRAF Mutation—Market Size
18.1. Total Market Size of BRAF NSCLC in the 7MM
18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM
18.3. United States Market Size
18.3.1. Total Market size of BRAF NSCLC in the United States
18.4. EU-5 Market Size
18.4.1. Germany Market Size
20. 18.4.2. France Market Size
18.4.3. Italy Market Size
18.4.4. Spain Market Size
18.4.5. United Kingdom Market Size
18.5. Japan Market Size
18.5.1. Total Market size of BRAF NSCLC in Japan
19. c-MET Mutation—Market Size
19.1. Total Market Size of c-MET NSCLC in the 7MM
19.2. Market Size of c-MET NSCLC by Therapeutic Class in the 7MM
19.3. United States Market Size
19.3.1. Total Market size of c-MET NSCLC in the United States
19.4. EU-5 Market Size
19.4.1. Germany Market Size
19.4.2. France Market Size
19.4.3. Italy Market Size
19.4.4. Spain Market Size
19.4.5. United Kingdom Market Size
19.5. Japan Market Size
19.5.1. Total Market size of c-MET NSCLC in Japan
20. EGFR Mutation—Market Size
20.1. Total Market Size of EGFR-positive NSCLC in the 7MM
20.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM
21. 20.3. United States Market Size
20.3.1. Total Market size of EGFR NSCLC in the United States
20.4. EU-5 Market Size
20.4.1. Germany Market Size
20.4.2. France Market Size
20.4.3. Italy Market Size
20.4.4. Spain Market Size
20.4.5. United Kingdom Market Size
20.5. Japan Market Size
20.5.1. Total Market size of NSCLC in Japan
21. ALK-Mutation—Market Size
21.1. Total Market Size of ALK NSCLC in the 7MM
21.2. Market Size of ALK NSCLC by Therapeutic Class in the 7MM
21.3. United States Market Size
21.3.1. Total Market size of ALK NSCLC in the United States
21.4. EU-5 Market Size
21.4.1. Germany Market Size
21.4.2. France Market Size
21.4.3. Italy Market Size
21.4.4. Spain Market Size
21.4.5. United Kingdom Market Size
21.5. Japan Market Size
22. 21.5.1. Total Market size of NSCLC in Japan
22. Market Access and Reimbursement of NSCLC Therapies
23. Market Drivers of NSCLC
24. Market Barriers of NSCLC
25. Appendix
25.1. Bibliography
25.2. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
Request a Webex Demo to get a walk-through of the
report: https://www.delveinsight.com/sample-request/non-small-cell-lung-
cancer-market
Related Reports:
Non-Small Cell Lung Cancer Epidemiology Forecast to 2030
Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and
Phase III Drugs Landscape, 2020
Non-Small Cell Lung Cancer Pipeline Insights, 2020
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm,
focused exclusively on the life science segment. With a wide array of smart
end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and
Medical devices companies formulate prudent business decisions for
improving their performances to stay ahead of the competitors.